首页> 外文OA文献 >887. High Rates of Virologic Suppression Achieved in HIV-1–Infected Adults Rapidly Starting Antiretroviral Therapy (ART) with the Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) 800/150/200/10 mg Regardless of Baseline Disease Characteristics: Week 48 Subgroup Analyses From the Phase 3 DIAMOND Trial

【2h】

887. High Rates of Virologic Suppression Achieved in HIV-1–Infected Adults Rapidly Starting Antiretroviral Therapy (ART) with the Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) 800/150/200/10 mg Regardless of Baseline Disease Characteristics: Week 48 Subgroup Analyses From the Phase 3 DIAMOND Trial

机译：887. HIV-1感染的成年人达到的病毒学抑制率快速启动抗逆转录病毒治疗（ART）与达尔努纳夫/钴/卵巢/ Emtrickabine / Tenofovir Alafenide（D / C / F / TAF）800 / 150/200 / 10 mg无论基线疾病特征如何：第48周亚组分析了第3阶段钻石试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Gregory D Huhn; Moti Ramgopal; Gordon Crofoot; Joseph Gathe; Sareh Seyedkazemi; Patricia Cosler; Richard Bruce Simonson; Donghan Luo; Keith Dunn;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 [J] . Eron Joseph J., Orkin Chloe, Cunningham Douglas, Antiviral Research . 2019,第期

机译：第9周的疗效和安全结果3阶段，随机祖母绿试验评估从增强蛋白酶抑制剂的切换加上Emtricitabine / Tenofovir Disoproxil富马酸莫霉素治疗达伦韦/钴/ Emtricitabine / Tenofovir Alafenaine的单片体方案（D / C / F / TAF）在治疗经验丰富的病毒学 - 被抑制的成年人与HIV-1一起生活
2. Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials [J] . Lathouwers Erkki, Wong Eric Y., Brown Kimberley, AIDS Research and Human Retroviruses . 2020,第1期

机译：每日48周的抗性分析曾经，单片机中达伦韦/诺福尼亚州/替斯塔布胺/替诺维尔（D / C / F / TAF）与HIV-1的成人中，III期随机琥珀和祖母绿试验
3. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment [J] . Wilkins Ed L., Cohen Calvin J., Trottier Benoit, AIDS care. . 2016,第3a4期

机译：利匹韦林/恩曲他滨/替诺福韦富马酸替莫索韦富马酸单药方案研究（STaR）的患者在抗逆转录病毒治疗未感染HIV-1的成人中治疗48周，结果与依法韦仑/恩曲他滨/替诺福韦富马酸二吡呋酯相比
4. 887. High Rates of Virologic Suppression Achieved in HIV-1–Infected Adults Rapidly Starting Antiretroviral Therapy (ART) with the Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) 800/150/200/10 mg Regardless of Baseline Disease Characteristics: Week 48 Subgroup Analyses From the Phase 3 DIAMOND Trial [O] . Gregory D Huhn, Moti Ramgopal, Gordon Crofoot, -1

机译：887.在达那鲁韦/库比西他/艾美他他滨/替诺福韦阿拉芬酰胺（D / C / F / TAF）的单片治疗方案（STR）中HIV-1感染的成年人快速开始抗逆转录病毒疗法（ART）的病毒学抑制率很高800 / 150/200/10 mg与基线疾病特征无关：第3 DIAMOND试验的第48周亚组分析
5. Week 48 Results of EMERALD: A Phase 3, Randomized, Non-inferiority Study Evaluating the Efficacy and Safety of Switching from Boosted-protease Inhibitors (bPI) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Regimens to the Once Daily (QD), Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-infected Adults [O] . Chloe Orkin, Jean-Michel Molina, Joel Gallant, 2017

机译：每周48个祖母绿的结果：第3期，随机的非劣升性研究，评估从增强蛋白酶抑制剂（BPI）加上的促蛋白（BPI）和替尼罗韦（FTC）/ Tenofovir Disoproxil umarate（TDF）方案的疗效和安全性对一次每日（QD ），在病毒学抑制的单片机/ Cobicistat / Emtricisabine / enftricitabine / Tenofovir Alafenainide（D / C / F / TAF）的单片植物（str），HIV-1感染的成年人

著录项

相似文献

相关主题

期刊订阅